Qiu Wenli, Wang Zhongqiu, Chen Rong, Shi Haibo, Ma Yanxia, Zhou Hongli, Li Muhan, Li Wenting, Chen Haibin, Zhou Hongguang
Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, Republic of China.
Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Cancer Manag Res. 2020 Nov 2;12:11121-11131. doi: 10.2147/CMAR.S269991. eCollection 2020.
Xiaoai Jiedu recipe (XJR), a formula long used by Chinese National Medical Professor Zhou Zhongying, has potent antitumor properties, but the molecular mechanism is still unclear. The aim of the study was to investigate the antitumor mechanism of XJR on hepatocellular carcinoma (HCC) by focusing on miRNA.
Three concentrations of XJR (low, middle, and high) were used to treat tumor xenograft mice models. Microarray technology was used to identify the differential expressed genes after XJR treatment, and bioinformatic tools and luciferase reporter assay to predict the potential pathways. HepG2 cells were transfected with inhibitor of miR-200b-3p to detect the effect of miR-200b-3p and Notch1 on tumor growth.
XJR effectively exerted anti-HCC effect both in vitro and in vivo. MiRNA chip analysis results showed that the expression of 75 miRNAs was upregulated and 158 miRNAs was downregulated in blood from XJR-treated mice. Further validation by using real-time polymerase chain reaction (RT-PCR) assay showed that the expression of five miRNAs (miR-453, miR-200b-3p, miR-135a-1-3p, miR-1960, miR-378a-5p, and miR-466f) was consistent with the results of miRNA chip analysis. Among them, miR-200b-3p was selected as candidate for further research. Results of the MTT, migration, and wound healing assays showed that down-expression of miR-200b-3p abrogated the effect of XJR on cell growth and metastasis. Luciferase reporter assay confirmed that Notch1 was the direct target of miR-200b-3p. XJR significantly decreased Notch1 expression in HepG2 cells, whereas miR-200B-3p inhibitor abrogated the XJR-induced decrease in Notch1 expression.
This study indicated that XJR could effectively inhibit HCC and might exert its antitumor effect through the miR-200b-3p/Notch1 axis. These findings provided new avenues for the use of XJR for prevention and treatment of HCC.
消癌解毒方(XJR)是国医大师周仲瑛长期使用的方剂,具有较强的抗肿瘤特性,但其分子机制仍不清楚。本研究旨在聚焦微小RNA(miRNA)探讨XJR对肝癌(HCC)的抗肿瘤机制。
采用三种浓度的XJR(低、中、高)处理肿瘤异种移植小鼠模型。利用基因芯片技术鉴定XJR处理后差异表达的基因,并通过生物信息学工具和荧光素酶报告基因检测预测潜在通路。将miR-200b-3p抑制剂转染至HepG2细胞中,以检测miR-200b-3p和Notch1对肿瘤生长的影响。
XJR在体外和体内均能有效发挥抗肝癌作用。miRNA芯片分析结果显示,XJR处理组小鼠血液中75种miRNA表达上调,158种miRNA表达下调。通过实时聚合酶链反应(RT-PCR)检测进一步验证,5种miRNA(miR-453、miR-200b-3p、miR-135a-1-3p、miR-1960、miR-378a-5p和miR-466f)的表达与miRNA芯片分析结果一致。其中,选择miR-200b-3p进行进一步研究。MTT、迁移和伤口愈合试验结果显示,miR-200b-3p的下调消除了XJR对细胞生长和转移的影响。荧光素酶报告基因检测证实Notch1是miR-200b-3p的直接靶点。XJR显著降低HepG2细胞中Notch1的表达,而miR-200B-3p抑制剂则消除了XJR诱导的Notch1表达降低。
本研究表明,XJR可有效抑制肝癌,可能通过miR-200b-3p/Notch1轴发挥其抗肿瘤作用。这些发现为XJR用于肝癌的预防和治疗提供了新途径。